



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: February 12, 2004

Signature:

(LI-Hsien Rin-Laures, M.D.)

Docket No.: 30764/39518
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Bennett et al.

Application No.: 10/618,553

Filed: July 11, 2003

Art Unit: 1636

For: Antisense Modulation of Survivin Expression Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The applicant requests that the documents listed on the attached Form PTO-1449 (Modified) be made of official record in the above-identified application and considered by the Examiner. Copies of documents A1-A2, B1 and C1-C13 have been previously submitted to the Patent Office in prior application U.S. Serial No. 09,918,186 from which priority is claimed under 35 U.S.C. §120. However, copies of these documents will be resubmitted at the Examiner's request.

This Information Disclosure Statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or 35 U.S.C. §103.

This Information Disclosure Statement is submitted before the receipt of an Office Action on the merits of the above-identified application and consequently should be considered by the Patent Office without payment of a fee. See 37 C.F.R. §1.97(b). However,

please charge any necessary fees due in connection with this Information Disclosure Statement to Deposit Account No. 13-2855. A copy of this paper is enclosed herewith.

Dated: February 12, 2004

Respectfully submitted,

By


Li-Hsien Rin-Laures, M.D.
Registration No.: 33,547
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant

Form PTO-1449 (Modified)				U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 30764/39518	Serial No. 10/618,553
INFORMATION DISCLOSURE STATEMENT				Applicant Bennett et al.		
				Filing Date July 11, 2003	Group TBA	

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
O'NEIL	A1	6,165,788	12/26/2000	Ackermann et al.			
FEB 17 2004	A2	5,801,154	09/01/1998	Baracchini et al.			

FOREIGN PATENT DOCUMENTS							
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	B1	WO 98/22589	5-28-1998	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	C1	Ambrosini <i>et al.</i> , "Induction of Apoptosis and Inhibition of Cell Proliferation by Survivin Gene Targeting," <i>J. Biol. Chem.</i> , 273:11177-11182 (1996).
	C2	Genbank Accession No. AW247335
	C3	Grossman <i>et al.</i> , "Expression of the Apoptosis Inhibitor, Survivin, in Nonmelanoma Skin Cancer and Gene Targeting in a Keratinocyte Cell Line," <i>Laboratory Investigation</i> , 29:1121-1126 (1999).
	C4	Li <i>et al.</i> , "Pleiotropic Cell-Division Defects and Apoptosis Induced by Interference with Survivin Function," <i>Nature Cell Biology</i> , 1:461-466 (1999).
	C5	European Supplementary Search Report. European Application No. EP 01 90 8740.
	C6	Branch, A.D., "A Good Antisense Molecule is Hard to Find," <i>TIBS</i> 23, 45-50 (1998).
	C7	Jen <i>et al.</i> , "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> , 18:307-319 (2000).
	C8	Adida <i>et al.</i> , "Anti-apoptosis Gene, Survivin, and Prognosis of Neuroblastoma," <i>Lancet</i> , 351:882-883 (1998).
	C9	Ambrosini <i>et al.</i> , "A Novel Anti-apoptosis Gene, Survivin, Expressed in Cancer and Lymphoma," <i>Nat. Med.</i> , 3:917-921 (1997).
	C10	Cohen, G.M., "Caspases: The Executioners of Apoptosis," <i>Biochem. J.</i> , 326:1-6 (1997).
	C11	Lu <i>et al.</i> , "Expression of a Novel Antiapoptosis Gene, Survivin, Correlated with Tumor Cell Apoptosis and p53 Accumulation in Gastric Carcinomas," <i>Cancer Res.</i> , 58:1808-1812 (1998).
	C12	Altieri, D., "Xa Receptor ERP-1," <i>FASEB</i> , 9:860-865 (1995).
	C13	Altieri, D., "Splicing of Effector Cell Protease Receptor-1 mRNA is Modulated by an Unusual Retained Intron," <i>Biochemistry</i> , 33:13848-13855 (1994).

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.</p>	